Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/31/2012EP2515946A2 Nanoconjugates and nanoconjugate formulations
10/31/2012EP2515942A2 Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
10/31/2012EP2515919A2 Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
10/31/2012EP2515917A1 Compositions and methods for eye whitening
10/31/2012EP2515916A1 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
10/31/2012EP2515915A1 Compositions and methods related to mirna in diabetic conditions
10/31/2012EP2515914A1 Tyrosine bioconjugation through aqueous ene-like reactions
10/31/2012EP2515913A2 Use of vitamin d glycosides and sulfates for treatment of disease
10/31/2012EP2515912A1 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
10/31/2012EP2515911A1 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
10/31/2012EP2515910A1 Use of polysaccharides for treating stress and anxiety
10/31/2012EP2515909A2 Fast dissolving pharmaceutical composition comprising lornoxicam
10/31/2012EP2515908A2 1,4-substituted piperazine derivatives and methods of use thereof
10/31/2012EP2515907A1 Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
10/31/2012EP2515906A2 Treating critically ill patients with intravenous ibuprofen
10/31/2012EP2515905A1 Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid
10/31/2012EP2515904A2 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
10/31/2012EP2515903A1 Compounds, preparations and uses thereof
10/31/2012EP2515902A1 Analogues for the treatment or prevention of flavivirus infections
10/31/2012EP2515901A2 Compositions and methods for treating obesity and diabetes
10/31/2012EP2515900A1 Method of treating atrial fibrillation
10/31/2012EP2515899A2 Methods and compositions for cardiovascular diseases and conditions
10/31/2012EP2515898A1 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
10/31/2012EP2515897A1 A combination for the treatment of osteoarthritis
10/31/2012EP2515896A1 Anticoagulant compounds and their use
10/31/2012EP2515895A2 Oral care compositions and methods
10/31/2012EP2515894A1 Compositions containing salmeterol, fluticasone and cromoglicic acid
10/31/2012EP2515893A2 Compositions comprising venlafaxine and celecoxib in the treatment of pain
10/31/2012EP2515892A2 Co-crystals of venlafaxine and celecoxib
10/31/2012EP2515891A1 3-keto-n-propargyl-1-aminoindan
10/31/2012EP2515890A1 Neuronal stimulation
10/31/2012EP2515889A2 Synergistic antiviral composition and use thereof
10/31/2012EP2515888A1 Dry powder formulation containing tiotropium for inhalation
10/31/2012EP2515887A1 Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
10/31/2012EP2515886A2 Transdermal therapeutic system for administering rivastigmine or derivatives thereof
10/31/2012EP2515885A1 Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
10/31/2012EP2515884A1 Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
10/31/2012EP2515883A1 Abt-263 capsule
10/31/2012EP2515881A2 Process for preparing tablets comprising 5- hydroxytryptophan and tryptophan
10/31/2012EP2515880A2 Novel pharmaceutical compositions of ranolazine
10/31/2012EP2515876A2 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
10/31/2012EP2515874A2 Calcipotriol monohydrate nanocrystals
10/31/2012EP2515873A1 Formulation comprising 1 h - quinazoline - 2, 4 - dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
10/31/2012EP2515872A1 Oral form of administration comprising entecavir
10/31/2012EP2515871A2 Solid pharmaceutical dosage form
10/31/2012EP2515866A2 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
10/31/2012EP2515865A2 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
10/31/2012EP2515864A1 Sustained release delivery devices
10/31/2012EP2515863A2 Slow release pharmaceutical compositions of iloperidone
10/31/2012EP2515862A1 Rapidly dispersing pharmaceutical formulation with cefdinir
10/31/2012EP2515860A1 Improved pharmaceutical compositions comprising cefdinir
10/31/2012EP2515859A1 Rapidly dispersing effervescent formulation
10/31/2012EP2515858A1 Pharmaceutical composition with high purity
10/31/2012EP2515857A1 The production method for effervescent tablet with cefdinir
10/31/2012EP2515856A2 Aerosol formulation for copd
10/31/2012EP2515855A2 Combination therapy for COPD
10/31/2012EP2515854A2 Aerosol formulation for copd
10/31/2012EP2515853A2 Combination therapy for COPD
10/31/2012EP2515852A1 Orodispersible tablet contained compacted sildenafil base
10/31/2012EP2515851A1 Treatment for inflammatory bowel disease
10/31/2012EP2515850A1 Pharmaceutical compositions comprising cefdinir as an active agent
10/31/2012EP2515849A1 Effervescent tablet and granule formulation comprising cefixime
10/31/2012EP2515848A1 Dry powder combination of tiotropium, a corticosteroid and a cromoglicic acid derivative
10/31/2012EP2515847A1 Combination of tiotropium, mometasone and a cromoglicic acid derivative in dry powder form
10/31/2012EP2515846A1 Dry powder combination of tiotropium, budesonide and a cromoglicic acid derivative
10/31/2012EP2515845A1 Dry powder combination of tiotropium, formoterol and a cromoglicic acid derivative
10/31/2012EP2515656A1 Aminobenzoquinazolinone m1 receptor positive allosteric modulators
10/31/2012EP2515655A1 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
10/31/2012EP2515654A1 Novel ergoline analogs
10/31/2012EP2515653A1 Pharmaceutical compositions for deterring misuse, abuse, and diversion
10/31/2012EP2515652A1 Compositions and methods for treatment of vitiligo
10/31/2012EP2515650A1 Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
10/31/2012EP2515647A1 Pheromone compositions and methods of use
10/31/2012EP2515646A2 Compositions comprising citrus flavonoids and specific cationic surface active agents for treating infestations with head lice
10/31/2012EP2155757B1 New progesterone receptor modulators
10/31/2012CN1956993B Macrolides with antiinflammatory activity
10/31/2012CN1461343B 多核苷酸 Polynucleotide
10/31/2012CN102762731A Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
10/31/2012CN102762577A 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
10/31/2012CN102762576A Benzoxazepin pi3k inhibitor compounds and methods of use
10/31/2012CN102762575A Multicyclic compounds and methods of use thereof
10/31/2012CN102762574A Benzoxepin pi3k inhibitor compounds and methods of use
10/31/2012CN102762573A Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
10/31/2012CN102762572A Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
10/31/2012CN102762571A Heterocyclic compounds as janus kinase inhibitors
10/31/2012CN102762570A Pyrazole derivatives as JAK inhibitors
10/31/2012CN102762569A Benzodiazepine bromodomain inhibitor
10/31/2012CN102762568A Pteridinones as inhibitors of polo - like kinase
10/31/2012CN102762567A Diaza-spiro[5.5]undecanes as orexin receptor antagonists
10/31/2012CN102762565A Pyrido[3,2-d]pyrimidine PI3[delta] inhibitor compounds and methods of use
10/31/2012CN102762564A Ghrelin receptor agonist for treatment of dyscrasia
10/31/2012CN102762563A Pyrazolo piperidine derivatives as nadph oxidase inhibitors
10/31/2012CN102762562A Pyrazolo piperidine derivatives as nadph oxidase inhibitors
10/31/2012CN102762561A Gamma secretase modulaters
10/31/2012CN102762560A Disubstituted heteroaryl-fused pyridines
10/31/2012CN102762559A Diphenyl-pyrazolopyrdine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators
10/31/2012CN102762558A Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
10/31/2012CN102762557A Triazolopyridines
10/31/2012CN102762556A Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same
10/31/2012CN102762554A (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
1 ... 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 ... 7860